PAB
vs
S
S&P/ASX 300
PAB
Over the past 12 months, PAB has underperformed S&P/ASX 300, delivering a return of -1% compared to the S&P/ASX 300's +4% growth.
Stocks Performance
PAB vs S&P/ASX 300
Performance Gap
PAB vs S&P/ASX 300
Performance By Year
PAB vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Patrys Ltd
Glance View
Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
